Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Stock - $0.001 par value
-
Shares outstanding
-
128M
-
Number of holders
-
134
-
Total 13F shares, excl. options
-
75M
-
Shares change
-
-2.63M
-
Total reported value, excl. options
-
$415M
-
Value change
-
-$14.6M
-
Put/Call ratio
-
0
-
Number of buys
-
84
-
Number of sells
-
-43
-
Price
-
$5.54
Significant Holders of Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) as of Q3 2024
148 filings reported holding CTKB - Cytek Biosciences, Inc. - Common Stock - $0.001 par value as of Q3 2024.
Cytek Biosciences, Inc. - Common Stock - $0.001 par value (CTKB) has 134 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 75M shares
of 128M outstanding shares and own 58.59% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (18.5M shares), VANGUARD GROUP INC (11.8M shares), BROWN CAPITAL MANAGEMENT LLC (9.49M shares), HHLR ADVISORS, LTD. (6.66M shares), STATE STREET CORP (4.17M shares), GEODE CAPITAL MANAGEMENT, LLC (2.67M shares), NEW YORK STATE COMMON RETIREMENT FUND (2.09M shares), WELLINGTON MANAGEMENT GROUP LLP (2.01M shares), DIMENSIONAL FUND ADVISORS LP (1.57M shares), and NORTHERN TRUST CORP (1.07M shares).
This table shows the top 134 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.